Core Viewpoint - The announcement of share reduction plans by shareholders of Anjiasi (688581.SH) indicates a strategic adjustment in their investment positions, with both shareholders planning to reduce their stakes by a total of 1,622,700 shares each, representing 2.0039% of the company's total shares [1][2] Group 1: Shareholder Reduction Plans - Shareholder Suzhou Yuansheng plans to reduce its holdings by up to 1,622,700 shares, with a maximum of 809,700 shares through centralized bidding and 813,000 shares through block trading [1] - Shareholder Hangzhou Tiantang Silicon Valley also plans to reduce its holdings by up to 1,622,700 shares, with the same distribution between centralized bidding and block trading [1] - The reduction period for centralized bidding is 90 natural days starting from 15 trading days after the announcement, while for block trading, it is 90 natural days starting from 3 trading days after the announcement [1] Group 2: Shareholding Structure - As of the announcement date, shareholder Suzhou Yuansheng holds 3,233,835 shares, accounting for 3.9934% of the total shares, with 2,309,882 shares from pre-IPO and 923,953 shares from the 2023 annual bonus shares [2] - Shareholder Hangzhou Tiantang Silicon Valley holds 1,622,700 shares, representing 2.0039% of the total shares, with 1,159,071 shares from pre-IPO and 463,629 shares from the 2023 annual bonus shares [2] - The pre-IPO shares held by these shareholders were released from restrictions and became tradable on May 20, 2024 [2] Group 3: IPO and Fundraising Details - Anjiasi raised a total of 182,032.60 million yuan from its IPO, with a net amount of 165,101.28 million yuan after deducting issuance costs, exceeding the original plan by 88,031.28 million yuan [3] - The funds raised are intended for projects including the production of 10 million medical endoscope devices, marketing network upgrades, and a minimally invasive medical device R&D center [3] - The total issuance costs amounted to 16,931.32 million yuan, with the lead underwriter, CITIC Securities, receiving 12,887.91 million yuan in fees [3] Group 4: Dividend Distribution - Anjiasi announced a cash dividend of 14.5 yuan (including tax) per 10 shares and a distribution of 4 bonus shares per 10 shares for the 2023 fiscal year, with the record date set for June 20 [4]

Core Viewpoint - Anjias (688581) announced that shareholders Xinjianyuan and Tiantang Silicon Valley plan to reduce their holdings by up to 4% of the company's shares, citing operational needs as the reason for the reduction [1] Group 1: Shareholder Actions - Shareholders Xinjianyuan and Tiantang Silicon Valley intend to reduce their holdings by a total of 162,270 shares, representing 2% of the company's total share capital [1] - The reduction is described as a "liquidation-style" reduction by Tiantang Silicon Valley [1] - Both shareholders had previously reduced their stakes between February and March, cashing out approximately 56.6 million yuan and 79 million yuan respectively [1] Group 2: Company Financials and Projects - Anjias reported a net fundraising amount of 1.65 billion yuan in 2023, with all funds received by May 16, 2023 [2] - As of February 28, 2025, 480 million yuan of the raised funds have been invested, with the minimally invasive medical device R&D center project planned to receive 166 million yuan, of which 69.63 million yuan has been invested, indicating a progress rate of 41.95% [2] - The project timeline has been extended from June 30, 2025, to December 31, 2026, due to market conditions and the need for careful planning of fund usage [2] Group 3: Company Performance - Anjias reported a revenue of 637 million yuan in 2024, a year-on-year increase of 25.14%, and a net profit attributable to shareholders of 293 million yuan, up 35.06% [3] - In the first quarter of 2025, the company achieved a revenue of 129 million yuan, a 15.3% increase year-on-year, with a net profit of 56.25 million yuan, up 6.6% [3] - The operating cash flow net amount decreased by 47.3% year-on-year to 7.53 million yuan [3]

Group 1 - The core point of the announcement is that shareholders of Hangzhou Anjisi Medical Technology Co., Ltd. plan to reduce their holdings in the company, with specific details on the number of shares and methods of reduction [1][2][3] - Shareholder Suzhou Yuansheng Private Fund Management Partnership intends to reduce up to 1,622,700 shares, accounting for 2.0039% of the total shares, through both centralized bidding and block trading [2][3] - Shareholder Hangzhou Paradise Silicon Valley Venture Capital Management Co., Ltd. also plans to reduce up to 1,622,700 shares, with the same percentage and methods as mentioned above [2][3] Group 2 - The reduction period for shares through centralized bidding will be within 90 natural days after 15 trading days from the announcement date, while block trading will commence 3 trading days after the announcement [2][3] - The announcement specifies that if there are any changes in the company's capital structure, such as stock dividends or capital increases, the number of shares to be reduced will be adjusted accordingly [2][3] - The shareholders have confirmed that they have no consensus on the reduction plan and have made prior commitments regarding their shareholding [3][4]

Core Viewpoint - The company, Anjisi Medical Technology Co., Ltd., has announced a differentiated cash dividend distribution plan, with a cash dividend of 1.3735 yuan per share, following the approval of its board and shareholders [1][2]. Dividend Distribution Plan - The company will distribute a cash dividend of 13.8 yuan for every 10 shares held, amounting to a total cash dividend distribution of approximately 111.2 million yuan (including tax) [2]. - The total share capital of the company is 80,978,794 shares, with 20,475 shares in the repurchase account, resulting in an actual participating share capital of 80,958,319 shares for the dividend distribution [2]. - The cash dividend distribution will not include capital reserve transfers or stock dividends [1][2]. Relevant Dates - The key dates for the dividend distribution are yet to be specified, including the record date, ex-dividend date, and cash dividend payment date [3]. Implementation of Distribution - The cash dividends will be distributed through the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, to shareholders registered by the record date [4]. - Shareholders who have not completed designated transactions will have their dividends held by the China Securities Depository and Clearing Corporation until the transactions are completed [4]. Taxation Policies - For individual shareholders holding shares for over one year, the dividend income is exempt from personal income tax, resulting in a net cash dividend of 1.3735 yuan per share [5][6]. - For shares held for less than one year, the company will not withhold personal income tax at the time of distribution, but the tax will be calculated based on the holding period when the shares are sold [5]. - The actual tax burden varies based on the holding period, with a 20% tax for shares held for one month or less, and a 10% tax for shares held between one month and one year [6]. Additional Information - The company will not withhold corporate income tax for institutional investors, who are responsible for determining their own tax obligations [8].

Key Points - Jiangnan Water received a stake increase from Lianan Life Insurance, reaching 5.03% of total shares [3] - Yingboer plans to transfer 100% equity of Zhuhai Dingyuan for 239 million yuan to optimize asset structure [4] - Chengbang Co. warns that its stock price fluctuations are not aligned with its fundamentals, as it has seen five consecutive trading days of price increases [6] - Weimais intends to invest 190 million yuan into its subsidiary for a new electric drive assembly project [7] - Fosun Pharma's subsidiary received EU GMP certification for its production facilities, indicating compliance with EU standards [8] - Jingwei Huikai plans to acquire an additional 12.44% stake in Nosi Micro, increasing its control in the semiconductor sector [9] - ST Tongmai will remove its delisting risk warning starting July 4, while continuing other risk warnings [10] - ST Modern seeks to apply for the removal of other risk warnings but will maintain delisting risk warnings [11] - Luxshare Precision is planning to issue H-shares for listing on the Hong Kong Stock Exchange [12] - Hainan Highway intends to purchase a 51% stake in Hainan Jiaokong Petrochemical, which will become a subsidiary [13] - Jucheng Co. plans to transfer 1.25% of its shares through a price inquiry [14] Performance Highlights - Foton Motor reported a 150.96% year-on-year increase in new energy vehicle sales for the first half of the year [15] - Jiangling Motors achieved a total vehicle sales of 172,700 units in the first half, up 8.15% year-on-year [16] - Changan Automobile's sales reached 1.3553 million units in the first half, with new energy vehicle sales growing by 49.05% [17] - Meinuohua expects a net profit increase of 142.84% to 174.52% for the first half of the year [18] - Jihong Co. anticipates a net profit increase of 55% to 65% for the first half of the year [19] - Nanjing Business Travel expects a net profit decrease of 67.4% to 78.27% for the first half of the year [20] - Madi Technology forecasts a net profit of 25 million to 27 million yuan, marking a turnaround from losses in the previous year [21] Major Contracts - Dash Intelligent signed a contract for an intelligent project worth 11.88 million yuan [22] - Jinyi Industrial won a bid for a 335 million yuan intercity railway materials procurement project [23] - Sichuan Road and Bridge signed a construction contract worth approximately 11.596 billion yuan [24] - Fulian Precision signed a cooperation framework agreement with Chuanfa Longmang for lithium battery material projects [26] Share Buybacks - Kweichow Moutai repurchased 72,000 shares in June, totaling 1.02 billion yuan [27] - Feiwo Technology plans to repurchase shares worth 25 million to 50 million yuan [28] - Nengte Technology intends to repurchase shares worth 300 million to 500 million yuan for capital reduction [29] - CATL has repurchased 6.641 million A-shares for a total of 1.551 billion yuan [30] Shareholding Changes - Renfu Pharmaceutical's shareholder plans to increase its stake by 1% to 2% [31] - Sanwei Xinan's shareholder intends to reduce its stake by up to 2% [33] - Data Port's shareholders plan to reduce their stakes by up to 2% [34] - Zhuzhou Design's controlling shareholders plan to reduce their stakes by up to 3% [35] - Tianji Co.'s controlling shareholders plan to reduce their stakes by up to 3% [36] - Anjisi's shareholders plan to reduce their stakes by up to 4% [37] Financing Activities - CITIC Securities received approval to issue up to 20 billion yuan in perpetual subordinated bonds [39]

Group 1 - Guizhou Moutai has repurchased a total of 3.3821 million shares as of June 30, 2025, accounting for 0.2692% of the total share capital, with a total expenditure of 5.202 billion yuan [2] - Luxshare Precision is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global financing capabilities and governance transparency [2] - Huazhong Xinchuang has received a project notification from a leading domestic eVTOL manufacturer for the development and supply of an intelligent cockpit multimedia display system [3] Group 2 - Meinohua expects a net profit of 46 million to 52 million yuan for the first half of 2025, representing a year-on-year increase of 142.84% to 174.52% [4] - Jiangnan Water has received a report from shareholder Lianan Life Insurance indicating an increase in shareholding by 46.99 million shares, representing 5.03% of the total share capital [5] - Huasen Pharmaceutical has received approval for clinical trials of its CX001 sustained-release tablets, marking a milestone for its innovative drug development platform [6] Group 3 - Zongshen Power anticipates a net profit growth of 70% to 100% for the first half of the year [7] - Yutong Bus reported a sales volume of 5,919 units in June, a year-on-year increase of 24.79% [7] - Guangzhou Port expects a 7.0% year-on-year increase in container throughput for June 2025 [7] Group 4 - Data Port's shareholders plan to reduce their holdings by up to 1.74% and 0.26% of the company's shares [9] - Humanwell Healthcare's shareholder plans to increase its stake by 1% to 2% [9] - Nengte Technology plans to repurchase shares worth between 300 million to 500 million yuan [10]

证券代码：688581 证券简称：安杰思 公告编号：2025-045 杭州安杰思医学科技股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持股的基本情况 截止本公告披露日，公司股东苏州元生私募基金管理合伙企业（有限合伙） －苏州工业园区新建元二期创业投资企业（有限合伙）（以下简称"新建元"）持 有杭州安杰思医学科技股份有限公司（以下简称"安杰思医学"或"公司"）股份 3,233,835 股，占公司总股本的 3.9934%，其中持有的股份来源为公司首发前股份 数 2,309,882 股，通过公司 2023 年年度派送红股获得的股份数 923,953 股。股东 杭州天堂硅谷创业投资管理有限公司－宁波天堂硅谷正汇股权投资合伙企业（有 限合伙）（以下简称"天堂硅谷"）持有公司股份 1,622,700 股，占公司总股本的 2.0039%，其中持有的股份来源为公司首发前股份数 1,159,071 股，通过公司 2023 年年度派送红股获得的股份数 463,629 股。上 ...

2024 年 2 月 7 日，安杰思召开第二届董事会第十一次会议，审议通过了《关 于以集中竞价交易方式回购公司股份方案的议案》，同意安杰思使用不低于人民 币 3,000 万元（含）不超过人民币 5,000 万元（含）的自有资金通过集中竞价的 交易方式回购安杰思已发行的部分人民币普通股（A 股）股票，回购股份将在未 来适宜时机全部用于员工持股计划或者股权激励，回购期限自第二届董事会第十 一次会议审议通过最终回购股份方案之日起不超过 12 个月。 中信证券股份有限公司 关于杭州安杰思医学科技股份有限公司 差异化权益分派的核查意见 中信证券股份有限公司（以下简称"保荐人"）作为杭州安杰思医学科技股 份有限公司（以下简称"安杰思"或"公司"）首次公开发行股票并在科创板上 市的保荐人，根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板 股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范 运作》等文件的要求，对安杰思差异化权益分派的事项进行了核查，具体情况如 下： 一、本次差异化权益分派的原因 2025 年 2 月 7 日，发行人披露《安杰思关于回购公司股份期限届满暨回购 实施结果的公告》 ...

证券代码：688581 证券简称：安杰思 公告编号：2025-044 杭州安杰思医学科技股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （1）差异化分红送转方案 | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/7/8 | 2025/7/9 | 2025/7/9 | 一、 通过分配方案的股东会届次和日期 本次利润分配方案经杭州安杰思医学科技股份有限公司（以下简称"公司"） 2025 年 5 月 16 日的2024年年度股东大会审议通过。 二、 分配方案 1. 发放年度：2024年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 （公司回购专用证券账户除外）。 是否涉及差异化分红送转：是 每股分配比例 每股现金红利1.3735元 相关日期 根据《上海证券交易所上市公司自律监管指引第 7 号 ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Anjiasi, a company in the medical device industry, which has a current PE ratio of 18.51, significantly lower than the industry average of 51.70 [1][2] - Anjiasi's total market capitalization is reported at 5.495 billion yuan, ranking 41st in the medical device sector based on PE ratio [1][2] - As of the first quarter of 2025, 11 institutions hold shares in Anjiasi, with a total of 17.7325 million shares valued at 1.26 billion yuan [1] Group 2 - Anjiasi specializes in the research, production, and sales of minimally invasive diagnostic and therapeutic instruments, with key products including GI, EMR/ESD, and ERCP diagnostic series [1] - The company achieved significant government honors, including recognition as a "Zhejiang Provincial Enterprise Technology Center" and "Zhejiang Provincial High-Growth Biopharmaceutical Enterprise" [1] - In the latest financial report for the first quarter of 2025, Anjiasi reported revenue of 129 million yuan, a year-on-year increase of 15.27%, and a net profit of 56.2483 million yuan, reflecting a 6.57% increase [1]